


AMENDMENTS TO THE CLAIMS

1. (Original) A compound of general formula (I)



I

wherein

R¹, R², R³ and R⁴ are independently hydrogen, halo, C₁-C₆ alkyl, -O(C₁-C₆ alkyl), -CON(R⁹)₂, -SOR⁹, -SO₂R⁹, -SO₂N(R⁹)₂, -N(R⁹)₂, -NR⁹COR⁹, -CO₂R⁹, -COR⁹, -SR⁹, -OH, -NO₂ or -CN;

each R⁹ is independently hydrogen or C₁-C₆ alkyl;

R⁵ and R⁶ are each independently hydrogen, or C₁-C₆ alkyl or together with the carbon atom to which they are attached form a C₃-C₇ cycloalkyl group;

R⁷ is hydrogen or C₁-C₆ alkyl

n is 1 or 2;

X is a bond or, when n is 2, X may also be a NR⁹ group;

wherein R⁹ is as defined above;

when X is a bond R⁸ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl, biphenyl or a 9-14 membered bicyclic or tricyclic heteroaryl group;

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

when X is a NR⁹ group R⁸ may additionally be phenyl, naphthyl or a 5-7 membered heteroaromatic ring; and

the R⁸ group is optionally substituted with one or more substituents selected from halo, C₁-C₆ alkyl, -O(C₁-C₆)alkyl, aryl, -O-aryl, heteroaryl, -O-heteroaryl, -CON(R⁹)₂, -SOR⁹, -SO₂R⁹, SO₂N(R⁹)₂, -N(R⁹)₂, -NR⁹COR⁹, -CO₂R⁹, -COR⁹, -SR⁹, -OH, -NO₂ or -CN;

wherein R⁹ is as defined above;

or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof.

2-30. (Cancelled)

31. (New) A compound as claimed in claim 1 wherein, independently or in any combination:

R¹ is halo or hydrogen;

R² is halo or hydrogen;

R³ is halo or hydrogen;

R⁴ is halo or hydrogen.

32. (New) A compound as claimed in claim 1 wherein R¹, R³ and R⁴ are hydrogen and R² is halo.

33. (New) A compound as claimed in claim 32 wherein R² is fluoro.

34. (New) A compound as claimed in claim 1 wherein R⁵ and R⁶ are each independently hydrogen or C₁-C₄ alkyl.

35. (New) A compound as claimed in claim 34 wherein at least one of R⁵ and R⁶ are hydrogen.

36. (New) A compound as claimed in claim 35 wherein both R⁵ and R⁶ are hydrogen.

37. (New) A compound as claimed in claim 1 wherein R⁷ is H or C₁-C₆ alkyl.

38. (New) A compound as claimed in claim 37 wherein R⁷ is methyl.

39. (New) A compound as claimed in claim 1 wherein n is 2.

40. (New) A compound as claimed in claim 1 wherein X is a bond and R⁸ is C₁-C₆ alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl, -CO₂R⁹ CON(R⁹)₂ or -SO₂R⁹, where R⁹ is as defined in claim 1.

41. (New) A compound as claimed in claim 41 wherein R⁸ is selected from the group consisting of a C₁-C₄ alkyl, biphenyl, and a bicyclic heteroaryl group, any of which may be substituted with phenyl, -CO₂R⁹ CON(R⁹)₂ or -SO₂R⁹, where R⁹ is H or C₁-C₄ alkyl.


42. (New) A compound as claimed in claim 1 wherein X is NR⁹, R⁹ is H or methyl and R⁸ is selected from the group consisting of:

phenyl optionally substituted with one or more halo, C₁-C₆ alkyl or -O(C₁-C₆ alkyl) groups;

C₁-C₆ alkyl, optionally substituted with aryl; and
heteroaryl.

43. (New) A compound as claimed in claim 42, wherein R⁸ is selected from the group consisting of phenyl, benzyl or pyridyl, any of which may optionally be substituted with one or more halo, methyl or methoxy groups.

44. (New) A compound of general formula (II):



II

wherein R¹, R², R³, R⁴, R⁵, R⁶, n, X, R⁷ and R⁸ are as defined for general formula (I); R¹⁰ is C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹¹)₂, CH((CH₂)_mO(C=O)R¹²)₂;

m is 1 or 2;

R¹¹ is hydrogen or methyl;

R¹² is C₁-C₁₈ alkyl.

45. (New) A compound as claimed in claim 15 wherein, independently or in any combination:

R¹ is halo or hydrogen;

R² is halo or hydrogen;

R³ is halo or hydrogen;

R⁴ is halo or hydrogen.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

46. (New) A compound as claimed in claim 44 wherein R¹, R³ and R⁴ are hydrogen and R² is halo.

47. (New) A compound as claimed in claim 46 wherein R² is fluoro.

48. (New) A compound as claimed in claim 44 wherein R⁵ and R⁶ are each independently hydrogen or C₁-C₄ alkyl.

49. (New) A compound as claimed in claim 48 wherein at least one of R⁵ and R⁶ are hydrogen.

50. (New) A compound as claimed in claim 38 wherein both R⁵ and R⁶ are hydrogen.

51. (New) A compound as claimed in claim 44 wherein R⁷ is H or C₁-C₆ alkyl.

52. (New) A compound as claimed in claim 51 wherein R⁷ is methyl.

53. (New) A compound as claimed in claim 44 wherein n is 2.

54. (New) A compound as claimed in claim 44 wherein X is a bond and R⁸ is C₁-C₆ alkyl, biphenyl or a bicyclic heteroaryl group, any of which may be substituted with halogen, phenyl, -CO₂R⁹ CON(R⁹)₂ or -SO₂R⁹, where R⁹ is as defined in claim 1.

55. (New) A compound as claimed in claim 54 wherein R⁸ is selected from the group consisting of a C₁-C₄ alkyl, biphenyl, a bicyclic heteroaryl group and a 5-7 membered heterocyclic ring, any of which may be substituted with phenyl, -CO₂R⁹ CON(R⁹)₂ or -SO₂R⁹, where R⁹ is H or C₁-C₄ alkyl.

56. (New) A compound as claimed in claim 44 wherein X is NR⁹, R⁹ is H or methyl and R⁸ is selected from the group consisting of:

phenyl optionally substituted with one or more halo, C₁-C₆ alkyl or -O(C₁-C₆ alkyl) groups;

C₁-C₆ alkyl, optionally substituted with aryl; and
heteroaryl.

57. (New) A compound as claimed in claim 56, wherein R⁸ is selected from the group consisting of phenyl, benzyl or pyridyl, any of which may optionally be substituted with one or more halo, methyl or methoxy groups.

58. (New) A compound selected from the group consisting of:

[3-(Butane-1-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
3-(Biphenyl-4-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
(3-Carboxymethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
(3-Carbamoylmethanesulfonyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
[5-Fluoro-3-(2-methanesulfonyl-ethanesulfonyl)-2-methyl-indol-1-yl]-acetic acid
[3-(Benzothiazole-2-sulfonyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(Benzothiazole-2-sulfinyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[5-Fluoro-2-methyl-3-(quinoline-2-sulfonyl)-indol-1-yl]-acetic acid
[5-Fluoro-2-methyl-3-(quinolin-8-ylsulfonyl)-indol-1-yl]-acetic acid
(5-Fluoro-2-methyl-3-phenylmethanesulfonyl-1H-indol-1-yl)-acetic acid
[3-(4-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(3-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(4-Fluoro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid

[3-(2-Chloro-phenylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
(3-Benzylsulfamoyl-5-fluoro-2-methyl-indol-1-yl)-acetic acid
[5-Fluoro-3-(2-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid
[5-Fluoro-3-(4-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid
(5-Fluoro-2-methyl-3-phenylsulfamoyl-indol-1-yl)-acetic acid
[3-(3,4-Dichloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[5-Fluoro-3-(3-methoxy-phenylsulfamoyl)-2-methyl-indol-1-yl]-acetic acid
(5-Fluoro-2-methyl-3-*m*-tolylsulfamoyl-indol-1-yl)-acetic acid
(5-Fluoro-2-methyl-3-p-tolylsulfamoyl-indol-1-yl)-acetic acid
[3-(4-Chloro-benzylsulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[3-(Benzyl-methyl-sulfamoyl)-5-fluoro-2-methyl-indol-1-yl]-acetic acid
[5-Fluoro-2-methyl-3-(pyridin-3-ylsulfamoyl)-indol-1-yl]-acetic acid;

and the C₁-C₆ alkyl, aryl, (CH₂)_mOC(=O)C₁-C₆alkyl, (CH₂)_mN(R¹¹)₂,

CH((CH₂)_mO(C=O)R¹²)₂ esters of any of the above; wherein

m is 1 or 2;

R¹¹ is hydrogen or methyl;

R¹² is C₁-C₁₈ alkyl.

59. (New) A process for the preparation of a compound of general formula (I) as claimed claim 1 and wherein n is 1 or 2 and X is a bond, the process comprising treating a compound of general formula (Ia), which is a compound of general formula (I) wherein n is 0 and X is a bond, by oxidation with a suitable oxidising agent.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

60. (New) A process for the preparation of a compound of general formula (I) as claimed in claim 1, the process comprising reacting a compound of general formula (II) as defined in claim 44 and wherein R¹⁰ is C₁-C₆ alkyl with a base.

61. (New) A method for the treatment of a disease or condition mediated by the action of PGD₂ at the CRTH2 receptor, the method comprising administering to a patient in need of such treatment a compound as claimed in claim 1 or a compound as claimed in claim 44.

62. (New) The method of claim 61, further comprising administering to the patient one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor.

63. (New) The method of claim 62 wherein the additional active agents are selected from the group consisting of β2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD₂ acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR-γ agonists and 5-lipoxygenase.

64. (New) The method of claim 63, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratadine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilomilast, inhibitors of TNFα converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

65. (New) A method for the treatment of a disease or condition selected from the group consisting of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis, autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury and chronic obstructive pulmonary disease; or rheumatoid arthritis, psoriatic arthritis and osteoarthritis, the method comprising administering to a patient in need of such treatment a compound as claimed in claim 1 or a compound as claimed in claim 44.

66. (New) The method of claim 65, further comprising administering to the patient one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD₂ at the CTRH2 receptor.

67. (New) The method of claim 66 wherein the additional active agents are selected from the group consisting of β2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD₂ acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR-γ agonists and 5-lipoxygenase.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

68. (New) The method of claim 67, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratadine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilomilast, inhibitors of TNF α converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

69. (New) A pharmaceutical composition comprising a compound as claimed in claim 1 together with a pharmaceutical excipient or carrier.

70. (New) A composition as claimed in claim 69 formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

71. (New) A composition as claimed in claim 70 formulated for oral, nasal, bronchial or topical administration.

72. (New) A composition as claimed in claim 69 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor.

73. (New) A composition as claimed in claim 72, wherein the additional active agents are selected from the group consisting of β 2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD₂ acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR- γ agonists and 5-lipoxygenase.

74. (New) A composition as claimed in claim 73, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratadine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilonilast, inhibitors of TNF α converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

75. (New) A pharmaceutical composition comprising a compound as claimed in claim 44 together with a pharmaceutical excipient or carrier.

76. (New) A composition as claimed in claim 75 formulated for oral, rectal, nasal, bronchial (inhaled), topical (including eye drops, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.

77. (New) A composition as claimed in claim 76 formulated for oral, nasal, bronchial or topical administration.

78. (New) A composition as claimed in claim 46 containing one or more additional active agents useful in the treatment of diseases and conditions mediated by PGD₂ at the CRTH2 receptor.

79. (New) A composition as claimed in claim 78, wherein the additional active agents are selected from the group consisting of β 2 agonists, corticosteroids, antihistamines, leukotriene antagonists, anti-IgE antibody therapies, anti-infectives, anti-fungals, immunosuppressants, other antagonists of PGD₂ acting at other receptors, inhibitors of phosphodiesterase type 4, drugs that modulate cytokine production, drugs that modulate the activity of Th2 cytokines IL-4 and IL-5, PPAR- γ agonists and 5-lipoxygenase.

80. (New) A composition as claimed in claim 79, wherein the additional active agents are selected from the group consisting of salmeterol, fluticasone, loratadine, montelukast, omalizumab, fusidic acid, clotrimazole, tacrolimus, pimecrolimus, DP antagonists, cilomilast, inhibitors of TNF α converting enzyme (TACE), blocking monoclonal antibodies, soluble receptors, rosiglitazone and zileuton.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100